# Diabetes Research Hub — Monitor Report

**Run date:** 2026-07-21 (automated, scheduled)
**Run type:** Review only — no files modified
**Prepared by:** diabetes-hub-monitor

---

## TL;DR — What's Actionable

1. **The data pipeline has stalled, not the monitor.** The three "latest" data files (`clinical_trials_latest.json`, `pubmed_recent_latest.json`, `hub_monitor_report.md`) have not refreshed since **2026-07-17** — now **4 days stale**. The snapshot series also stops at 07-17. That means *nothing in the underlying data has changed since the 07-20 report ran.* The single most useful action today is to run the three baseline scripts locally. **[Certain — file mtimes]**

2. **Yesterday's headline (AstraZeneca elecoglipron Phase 3) is the same event, not a new one.** The four elecoglipron trials flipping `NOT_YET_RECRUITING → RECRUITING` happened in the 07-10→07-17 window and were already reported on 07-20. No new snapshot exists to confirm further movement. Do not re-log it as a new finding. **[Certain]**

3. **No genuinely new trial or literature signal this cycle** — because there is no new data to diff. The 07-16→07-17 hub diff (1 trial in, 1 out; 28 PubMed papers in, 27 out; 3 cross-domain papers) is the most recent real change and is already captured. **[Certain]**

4. **Web breaking-news check could NOT be completed** — the search service returned repeated 529 (overloaded) errors across ~6 attempts over several minutes. This step should be re-run manually. Prior run (07-20) found the ADA 2026 Phase 3 readouts (retatrutide, orforglipron ACHIEVE) are >4 weeks old and not new. **[Certain the check failed; Likely nothing new, unverified this cycle]**

---

## File System Status

| File | Last modified | Age | Status |
|------|--------------|-----|--------|
| `hub_monitor_report.md` | 2026-07-17 02:16 | 4 d | **Stale** |
| `clinical_trials_latest.json` | 2026-07-17 02:05 | 4 d | **Stale** |
| `pubmed_recent_latest.json` | 2026-07-17 02:06 | 4 d | **Stale** |
| `literature_gap_data.json` | 2026-07-18 03:11 | 3 d | OK |
| `literature_gap_report.md` | 2026-07-20 03:07 | 1 d | Fresh |

All five expected inputs are present. Latest dated snapshots: `clinical_trials_snapshot_2026-07-17.json` and `pubmed_recent_snapshot_2026-07-17.json`. No 07-18/19/20/21 snapshots exist — the baseline collectors have not run for 4 days.

The hub monitor's own scan flagged **827 result files older than 14 days**; these are archival snapshots, `agent_state` backups, and dashboards, not a concern. The three "latest" files above are the ones that matter.

**To refresh (run locally):**
```
python baseline_clinical_trials.py
python baseline_pubmed_alerts.py
python hub_monitor.py
```

---

## Clinical Trial Changes

**Basis:** latest available snapshot pair `2026-07-10 → 2026-07-17` (same window as the 07-20 report — no newer data exists).

Latest corpus: **858 trials** across 5 categories (T1D Cure & Cell Therapy 152, T1D Immunotherapy & Prevention 76, T2D Novel Therapies 147, Diabetes Technology 236, Recently Completed w/ Results 321).

**Added (8):** NCT05086445 (Lilly, orforglipron Ph1, COMPLETED w/ results 07-16), NCT05254002 (Bayer Ph2), NCT05574699 (Johns Hopkins), NCT04717050 (Dana-Farber), NCT07699380 (UW Ph2 RECRUITING), NCT07702890 (Gubra Ph1/2), NCT07696988 (VA), NCT07696273 (Indiana U, breath sensor).

**Removed (2):** NCT07087340 (UniBE hybrid closed-loop), NCT06650007 (HRS9531 Ph3).

**Status changes (6)** — all confirm the AstraZeneca elecoglipron Phase 3 launch already flagged 07-20:
- NCT07662044, NCT07662109, NCT07662135, NCT07662213 → RECRUITING (elecoglipron Ph3)
- NCT07668388 (Novo Nordisk Ph2) → RECRUITING
- NCT07215312 (Lilly LY3938577) RECRUITING → ACTIVE_NOT_RECRUITING

**New results posted:** 0 in this window.

**Key Phase 3 programs to keep watching (current status):**
- **Vertex VX-880 / zimislecel** — NCT06832410 & NCT04786262 both RECRUITING (Ph3). VX-264 (NCT05791201) Ph1/2 ACTIVE_NOT_RECRUITING. *Note: PubMed shows 0 papers mentioning "zimislecel" — literature has not yet caught up to the trial program.*
- **Lilly baricitinib in T1D** — NCT07222332 (preserve beta-cell) & NCT07222137 (delay Stage 3) both RECRUITING Ph3. Immunotherapy repurposing; Tier-1-relevant (Clinical Trial Intelligence + Drug Repurposing).
- **Sanofi teplizumab** — NCT07088068 RECRUITING Ph3 (vs comparator).
- **Novo icodec / CagriSema** — icodec T1D (NCT07076199) RECRUITING; CagriSema NCT07564414 RECRUITING, NCT07282613 NOT_YET_RECRUITING.
- 52 Phase 3 trials currently RECRUITING overall.

---

## PubMed Highlights

**Basis:** `pubmed_recent_latest.json` (07-17, 30-day lookback, 158 unique papers, 16 domains).

**Cross-domain papers (highest priority — 12 total, 3 new in last diff):**
- **[42459945]** *A framework for assessing algorithmic discrimination risks in training data: pediatric T1D* — AI/ML × Closed Loop AP × Health Equity. **Hits three Tier-1-adjacent domains; flag for review.**
- [42458355] Socioeconomic gradients in hypertension prevalence/management — AI/ML × Health Equity.
- [42436543] Healthcare inequalities dynamics in T2D — T2D Remission × Health Equity.
- [42453334] Noncoding RNAs for diabetes (in silico → clinic) — Biomarker × LADA.
- [42459212] / [42458730] Precision nutrition / multi-omic BMI modelling — Microbiome × Multi-Omics (Tier-1 Multi-Omics relevant).
- [42419792] Comparative obesity drug effects (orforglipron × retatrutide × CagriSema) — key-therapy triple.

**Key-therapy tracker (papers / total hits, last 30 d):**

| Therapy | Papers | Total hits |
|---|---|---|
| dapagliflozin | 5 | 52 |
| orforglipron | 5 | 10 |
| CagriSema | 5 | 6 |
| retatrutide | 4 | 4 |
| teplizumab | 4 | 4 |
| icodec | 3 | 3 |
| baricitinib | 2 | 2 |
| **zimislecel** | **0** | **0** |

**Volume note:** Domain query volumes are dominated by AI/ML (260 total hits), Microbiome (186), GLP-1 New (167), Biomarker (166) — consistent with prior cycles. LADA (12) and Stem Cell Cure (17) remain the thinnest, matching the gap analysis below. No anomalous spike this cycle.

---

## Gap Analysis Summary

**Basis:** `literature_gap_report.md` (generated 07-20; 30 domains, 435 pairs). Validation level: **BRONZE** (single analytical source — expert confirmation required per Doctrine).

**Top 5 potentially meaningful under-researched intersections (Gap Score 100, 0 joint pubs):**
1. **Treg / CAR-T × Neuropathy** — immune-mediated diabetic neuropathy as a Treg-modulation target; no bridging work.
2. **Beta Cell Regen × Health Equity** — no equity analysis of who accesses emerging cell therapies.
3. **Treg / CAR-T × Health Equity** — no equity analysis of CAR-Treg/TCR-Treg access.
4. **Glucokinase × Health Equity** — no global-access analysis for the GKA drug class.
5. **Gene Therapy × LADA** — LADA's autoimmune mechanism is a gene-therapy candidate; no crossover.

**Alignment with our Tier 1 contribution areas (RESEARCH_DOCTRINE):**
- Four of the top five involve **Health Equity** — squarely Tier 1 #6 (Epidemiological / disparity analysis) and computationally tractable with public GBD/CDC/IDF data. This is the strongest actionable cluster: an equity-of-access synthesis over emerging cell/immuno/GKA therapies would be original and low-barrier.
- **Beta Cell Regen** and **Treg/CAR-T** gaps also touch Tier 1 #2 (Literature Synthesis) — good candidates for a PRISMA-style scoping review.
- Caveat per Doctrine: several 100-score pairs are **methodologically distinct** (e.g., GWAS × Closed-Loop AP) and should be deprioritized; the equity pairs are the ones worth escalating to expert review.

---

## Breaking News

**Status: NOT COMPLETED THIS CYCLE.** The web search service returned repeated 529 (overloaded) errors on every attempt (~6 tries over several minutes). No breaking-news scan was performed. **Recommend re-running Step 3 manually or on the next scheduled run.**

Carry-over from 07-20 (unverified today): ADA 2026 Phase 3 readouts (retatrutide, orforglipron ACHIEVE) are >4 weeks old and not new news.

---

## Recommended Actions

1. **Run the three baseline scripts locally to un-stall the pipeline** — this is the top priority. Data is 4 days stale and no new snapshots have been produced since 07-17:
   ```
   python baseline_clinical_trials.py
   python baseline_pubmed_alerts.py
   python hub_monitor.py
   ```
   Consider checking why the daily collectors stopped after 07-17 (scheduler, network, or API-key issue) — the gap is unusual versus the previously near-daily cadence.
2. **Re-run the web breaking-news check** (Step 3) once the search service recovers — it failed with server errors this cycle.
3. **Review cross-domain paper [42459945]** (algorithmic discrimination in pediatric T1D) — AI/ML × Closed Loop × Health Equity; relevant to Tier 1 #5 and #6.
4. **Escalate the Health-Equity gap cluster to expert review** — 4 of the top 5 gaps involve equity of access to emerging therapies (Beta Cell Regen, Treg/CAR-T, Glucokinase). Aligns with Tier 1 #6; strong low-barrier synthesis opportunity. All findings remain BRONZE until expert-confirmed.
5. **Add tracker entries** for the AstraZeneca elecoglipron Phase 3 program (NCT07662044/109/135/213) and the Lilly baricitinib T1D Phase 3 pair (NCT07222332/137) if not already logged — both are Tier-1 Clinical Trial Intelligence items. *(Write action — left for user; this run modified no files.)*
6. **Note the zimislecel literature blind spot** — Vertex's lead Phase 3 cell therapy has 0 PubMed hits under that name. If tracking it, the PubMed alert query may need the alternate name/synonyms added.

---

*Generated by diabetes-hub-monitor — review run, no source files modified. Evidence levels noted inline per RESEARCH_DOCTRINE. All gap classifications are BRONZE pending expert validation.*
